Things have started to turn up for this midcap name. Look for these shares to end the year on an up note.
With two approaches on the same page, here's how we'd trade this drugmaker's stock.
Let me show you an options play and tell why now could be the time to use it.
Unbelievably, there may be more interest in weight loss than AI right now.
It's small-cap earnings season and the market is under pressure. This may create some good opportunities.
Here's how traders can play the stock.
Is this a buy the dip move?
These small and mid-cap names have seen major news of late.
As we check the charts, I have two new price targets.
AMGN's quarterly report is due in early August, so will buying the stock now pose any side effects?